Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kroll

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Nature Communications|March 14, 2024
High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug designVictoria I Cushing, Adrian F Koh, Junjie Feng, et al.
Molecular Cancer Therapeutics|March 17, 2018
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer TreatmentHetal Patel, Manikandan Periyasamy, Georgina P Sava, et al.
The Plant Cell|August 16, 2020
In Vivo NADH/NAD<sup>+</sup> Biosensing Reveals the Dynamics of Cytosolic Redox Metabolism in PlantsJanina Steinbeck, Philippe Fuchs, Yuri L Negroni, et al.
Cancer Research|July 30, 2009
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activitySimak Ali, Dean A Heathcote, Sebastian H B Kroll, et al.
Nature Communications|December 20, 2024
A family of NADPH/NADP<sup>+</sup> biosensors reveals in vivo dynamics of central redox metabolism across eukaryotesMarie Scherschel, Jan-Ole Niemeier, Lianne J H C Jacobs, et al.
Journal of Medicinal Chemistry|November 18, 2010
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administrationDean A Heathcote, Hetal Patel, Sebastian H B Kroll, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Nature Communications|March 14, 2024
High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug designVictoria I Cushing, Adrian F Koh, Junjie Feng, et al.
Molecular Cancer Therapeutics|March 17, 2018
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer TreatmentHetal Patel, Manikandan Periyasamy, Georgina P Sava, et al.
The Plant Cell|August 16, 2020
In Vivo NADH/NAD<sup>+</sup> Biosensing Reveals the Dynamics of Cytosolic Redox Metabolism in PlantsJanina Steinbeck, Philippe Fuchs, Yuri L Negroni, et al.
Cancer Research|July 30, 2009
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activitySimak Ali, Dean A Heathcote, Sebastian H B Kroll, et al.
Nature Communications|December 20, 2024
A family of NADPH/NADP<sup>+</sup> biosensors reveals in vivo dynamics of central redox metabolism across eukaryotesMarie Scherschel, Jan-Ole Niemeier, Lianne J H C Jacobs, et al.
Journal of Medicinal Chemistry|November 18, 2010
A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administrationDean A Heathcote, Hetal Patel, Sebastian H B Kroll, et al.
Pageof 4